Allie Nawrat

You can get in touch with Allie on Alexandra.Nawrat@verdict.co.uk

All articles by Allie Nawrat

1. FDA expands Ibrance’s label to include male breast cancer patients

   Pfizer has announced that the US Food and Drug Administration (FDA) has accepted its request to expand the indications for…
   Read More…

   5 Apr
2. Gilead submits sNDA to FDA to expand HIV label for Descovy

   Gilead has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for antiviral Descovy…
   Read More…

   5 Apr
3. NICE recommends BMS’ Opdivo-Yervoy combination for RCC

   Bristol-Myers Squibb (BMS) has announced that the National Institute of Health and Care Excellence (NICE) has recommends Opdivo (nivolumab) and…
   Read More…

   5 Apr
4. ViiV announces long-term positive results for Juluca combination

   London-based ViiV Healthcare has announced three-year results from its Sword-1 and Sword-2 trials. These trials evaluated viral suppression rates of…
   Read More…

   4 Apr
5. NIH initiates first clinical trial of universal influenza vaccine

   The US National Institutes of Health (NIH) has announced it has enrolled patients into the first Phase I trial of…
   Read More…

   4 Apr
6. China’s NMPA approves Novartis’ Cosentyx and Merck’s Keytruda

   Novartis has announced that the Chinese National Medical Product Administration (NMPA) has approved its plaque psoriasis drug Cosentyx (secukinumab). Cosentyx…
   Read More…

   3 Apr
7. Sangamo announces promising early results for haemophilia A gene therapy

   California-based Sangamo Therapeutics, alongside its partner Pfizer, has announced interim results from Phase I/II Alta study evaluating an investigational SB-525…
   Read More…

   3 Apr
8. FDA grants AstraZeneca-Merck’s selumetinib breakthrough therapy designation

   AstraZeneca has announced the US Food and Drug Administration (FDA) has granted selumetinib, a MEK 1/2 inhibitor co-commercialised with Merck,…
   Read More…

   1 Apr
9. Penn presents positive results for targeted leukaemia drug

   Researchers from the University of Pennsylvania (Penn) Abramson Cancer Center have announced findings from the ADMIRAL trial of gilteritinib in…
   Read More…

   1 Apr
10. NICE recommends AstraZeneca’s Imfinzi through Cancer Drugs Fund

    The UK’s National Institute of Health and Care Excellence (NICE) has published its final guidance for AstraZeneca’s Imfinzi (durvalumab), in…
    Read More…

    29 Mar